A breakthrough in cell biology has just been made at the University of Cincinnati, where researchers have for the first time visualized the structure of a critical protein complex that regulates immune responses and tissue development. The discovery, published in Cell Reports, could unlock new treatments for chronic inflammatory diseases by targeting the iRhom1-ADAM17 interaction—a molecular puzzle scientists have chased for decades.
Why This Discovery Matters: The 30-Year Mystery Solved
The Seegar Lab at UC’s College of Medicine has done what no other team could: capture the atomic-level structure of iRhom1 bound to the ADAM17 enzyme using cryogenic electron microscopy. This isn’t just a technical achievement—it’s a biological breakthrough. ADAM17 is a master regulator of cell signaling, slicing off proteins from cell surfaces to control everything from immune responses to tissue repair. But how it gets activated by signals from inside the cell has remained a mystery since its discovery in the 1990s.
“ADAM17 is rapidly activated in response to changes in intracellular signaling networks, yet how these signals are transmitted across the cell membrane to where ADAM17 resides has remained a long-standing question in the field.”
The lab’s work reveals that iRhom1 and iRhom2—two proteins that partner with ADAM17—act as molecular relays, transmitting signals from inside the cell to the enzyme’s surface. What’s even more surprising? Despite their nearly identical structures, these proteins have distinct functions, a discovery that could explain why some inflammatory diseases respond differently to treatments. As Joe Maciag, PhD, a research scientist in the Seegar Lab, put it: “While the structures are remarkably similar, their functions are divergent. The nuance of their sequence determines which substrates they recognize and cleave.”
A Drug Target Hidden in Plain Sight
This isn’t just academic curiosity. ADAM17 is already a known drug target for chronic inflammatory diseases like psoriasis and rheumatoid arthritis. But the UC team’s discovery takes it further: by pinpointing how iRhom1 and iRhom2 fine-tune ADAM17’s activity, researchers can now design therapies that zero in on specific pathways—potentially reducing side effects and improving efficacy. The study even identified a mutation in iRhom1 linked to cardiomyopathy, suggesting these proteins could be involved in heart disease as well.
The implications are vast. If iRhom2, for example, is confirmed as a driver of ADAM17’s specificity in inflammation, it could become a new target for drugs that avoid the broad-spectrum side effects of current treatments. “It’s what’s been missing in our field for 30 years,” Seegar said, underscoring the urgency of this research.
UC’s Research Ecosystem: From Lab to Real-World Impact
The University of Cincinnati isn’t just a research powerhouse—it’s a proving ground for turning lab discoveries into real-world applications. The Seegar Lab’s work builds on their 2025 breakthrough, where they visualized ADAM17 bound to iRhom2, a finding that already caught the attention of pharmaceutical researchers. Now, with the iRhom1 structure in hand, the team is poised to accelerate drug development.
But UC’s impact extends beyond the lab. The university’s cooperative education program, which integrates paid professional experience into academic studies, has produced graduates like Megan Pando, a former PacSun co-op who turned her hands-on experience into Makers Social, a DIY project bar that secured a deal on Shark Tank. This model—where research meets real-world problem-solving—could be a blueprint for translating biomedical breakthroughs into commercial success.
What Comes Next: The Race for Clinical Applications
So what happens now? The UC team is already collaborating with pharmaceutical companies to explore iRhom1 and iRhom2 as drug targets. The next phase will involve high-throughput screening to identify small molecules that can selectively modulate these proteins without triggering off-target effects. If successful, this could lead to a new class of anti-inflammatory drugs within the next five to ten years.
There are also unanswered questions. Why do iRhom1 and iRhom2 have such different roles despite their similar structures? Could mutations in these proteins contribute to other diseases beyond cardiomyopathy? And how might this research intersect with UC’s other health-focused initiatives, like the newly opened Morrison Center, a $10 million facility training occupational and physical therapists—two professions critical to patient care in inflammatory and autoimmune diseases?
The road from lab discovery to clinical application is long, but the foundation has been laid. With UC’s track record of turning research into impact—and its commitment to experiential learning—the stage is set for this breakthrough to change how we treat chronic inflammation.
A Note on the Competition: Why UC Leads
While other universities like the University of the Cumberlands and the University of Charleston have made strides in education and healthcare training, UC’s strength lies in its interdisciplinary approach. The Seegar Lab’s use of cryogenic electron microscopy—a technique requiring both cutting-edge equipment and deep biological expertise—demonstrates how UC is leveraging its resources to stay ahead. The university’s Center for Advanced Structural Biology, where this research was conducted, is a rare facility capable of handling such complex molecular visualizations.
This isn’t just about beating other institutions to the punch. It’s about solving a problem that has stumped researchers for generations. And with UC’s co-op model, there’s a real chance that the next generation of scientists—those who benefit from hands-on experience—will be the ones to turn this discovery into life-changing therapies.
The Big Picture: What This Means for Medicine
The UC discovery is more than a scientific milestone—it’s a reminder of how fundamental research can reshape medicine. By unraveling the mechanics of ADAM17 activation, scientists may finally unlock precise treatments for diseases that have resisted cure for decades. The work also highlights the importance of investing in structural biology, a field that often flies under the radar but is critical for understanding how proteins function at the most basic level.
For patients with chronic inflammatory conditions, this could mean fewer side effects, more targeted therapies, and a better quality of life. For the pharmaceutical industry, it opens the door to a new era of drug design. And for UC, it reinforces its reputation as a leader in both research and real-world impact.
The next few years will tell whether this breakthrough translates into clinical breakthroughs. But one thing is clear: the University of Cincinnati has just added another chapter to its legacy of innovation.
